CDX model based genome-scale CRISPR KO screens for modulators of KRAS (G12C) inhibitor sensitivity

被引：0
|
作者：
Zhao, Haixin
Zhai, Fangzheng
Li, Bin
Fan, Qiangqiang
Peng, Zhengang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-257
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
257
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Discovery of MK-1084, a low dose selective clinical stage KRAS G12C inhibitor
    Maddess, Matthew L.
    Sloman, David L.
    Ma, Xiaoshen
    Palani, Anandan
    Stoeck, Alexander
    Sather, Aaron C.
    Solban, Nicolas
    Duggal, Ruchia
    Ballard, Jeanine
    Munsell, Erik V.
    Chen, Lin-Chi
    Han, Yongxin
    Miller, Richard
    Gathiaka, Symon
    Brynczka, Christopher
    Li, Hongming
    Yang, Ruojing
    Brynczka, Christopher
    Day, Phil
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [32] The FAK/SRC axis mediates resistance to KRAS G12C inhibitors and its blockade can overcome KRAS inhibitor resistance
    Shibata, Yuji
    Udagawa, Hibiki
    Nilsson, Monique B.
    Robichaux, Jacqulyne
    Galan-Cobo, Ana
    Negrao, Marcelo
    Molkentine, David P.
    He, Junqin
    Poteete, Alissa
    Qian, Yu
    Huang, Qian
    Skoulidis, Ferdinandos
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (06)
  • [33] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
    Tereza Vaclova
    Atanu Chakraborty
    James Sherwood
    Sarah Ross
    Danielle Carroll
    J. Carl Barrett
    Julian Downward
    Elza C. de Bruin
    Scientific Reports, 12
  • [34] Quantifying KRAS G12C Covalent Drug Inhibitor Activity in Mouse Tumors Using Mass Spectrometry
    Tran, John C.
    Hunsaker, Thomas
    Bell, Christina
    Ma, Taylur P.
    Chan, Emily
    Larrocha, Pablo Saenz-Lopez
    Homyk, Kelsey
    Liu, Liling
    La, Hank
    Mao, Jialin
    de la Cruz, Cecile C.
    Yu, Kebing
    Beresini, Maureen
    Forrest, William F.
    Xiao, Yang
    Jang, Anne
    Samus, Natalia
    Stesco, Nicholas Dupuis
    Mentinova, Marija
    Parent, Stephane
    Pottiez, Gwenael
    Schirm, Michael
    Purkey, Hans E.
    Liu, Yichin
    Merchant, Mark
    ANALYTICAL CHEMISTRY, 2023, 95 (11) : 4834 - 4839
  • [35] Addressing Atropisomerism in the Development of Sotorasib, a Covalent Inhibitor of KRAS G12C: Structural, Analytical, and Synthetic Considerations
    Lanman, Brian A.
    Parsons, Andrew T.
    Zech, Stephan G.
    ACCOUNTS OF CHEMICAL RESEARCH, 2022, 55 (20) : 2892 - 2903
  • [36] Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition
    Vaclova, Tereza
    Chakraborty, Atanu
    Sherwood, James
    Ross, Sarah
    Carroll, Danielle
    Barrett, J. Carl
    Downward, Julian
    de Bruin, Elza C.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [37] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Nakayama, Ayako
    Nagashima, Takeyuki
    Nishizono, Yoshihiro
    Kuramoto, Kazuyuki
    Mori, Kenichi
    Homboh, Kazuya
    Yuri, Masatoshi
    Shimazaki, Masashi
    BRITISH JOURNAL OF CANCER, 2022, 126 (05) : 744 - 753
  • [38] Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models
    Ayako Nakayama
    Takeyuki Nagashima
    Yoshihiro Nishizono
    Kazuyuki Kuramoto
    Kenichi Mori
    Kazuya Homboh
    Masatoshi Yuri
    Masashi Shimazaki
    British Journal of Cancer, 2022, 126 : 744 - 753
  • [39] Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers
    Khan, Husain Yar
    Nagasaka, Misako
    Li, Yiwei
    Aboukameel, Amro
    Uddin, Md. Hafiz
    Sexton, Rachel
    Bannoura, Sahar
    Mzannar, Yousef
    Al-Hallak, Mohammed Najeeb
    Kim, Steve
    Beydoun, Rafic
    Landesman, Yosef
    Mamdani, Hirva
    Uprety, Dipesh
    Philip, Philip A.
    Mohammad, Ramzi M.
    Shields, Anthony F.
    Azmi, Asfar S.
    CANCER RESEARCH COMMUNICATIONS, 2022, 2 (05): : 342 - 352
  • [40] Structure- based drug discovery of a selective, covalent KRas G12C inhibitor with oral activity in animal models of cancer
    Fischer, John
    Baer, Brian
    Ballard, Joshua
    Blake, James
    Bouhana, Karyn
    Brandhuber, Barbara
    Briere, David
    Burgess, Laurence
    Burkard, Michael
    Chiang, Harrah
    Chicarelli, Mark
    Christensen, James
    Davidson, Kevin
    Gaudino, John
    Hallin, Jill
    Hanson, Lauren
    Hee, Kenneth
    Hicken, Erik
    Hinklin, Ronald
    Marx, Matthew
    Mejia, Macedonio
    Olson, Peter
    Savechenkov, Pavel
    Sudhakar, Niranjan
    Tang, Tony
    Vigers, Guy
    Zecca, Henry
    Fell, Jay
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
12345